{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone+Quadrivalent",
    "query": {
      "intervention": "Fluzone Quadrivalent"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 189,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone+Quadrivalent&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T07:56:04.197Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04969276",
      "title": "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Inactivated Influenza High Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 mRNA Vaccine (nucleoside modified)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2021-07-16",
      "completion_date": "2022-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 6,
      "location_summary": "Glendale, Arizona • San Diego, California • Vista, California + 3 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04969276"
    },
    {
      "nct_id": "NCT04120194",
      "title": "Phase 3 Pivotal Trial of NanoFlu™ in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "NanoFlu",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone Quadrivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 2654,
      "start_date": "2019-10-14",
      "completion_date": "2020-12-13",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 19,
      "location_summary": "Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 16 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Nampa",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04120194"
    },
    {
      "nct_id": "NCT04451954",
      "title": "Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza Immunisation",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Quadrivalent RIV with H3 strain 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent RIV with H3 strain 1 and adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent RIV with H3 strain 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent RIV with H3 strain 2 and adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent RIV with 2018-2019 NH H3 strain",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2020-07-02",
      "completion_date": "2021-09-20",
      "has_results": false,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04451954"
    },
    {
      "nct_id": "NCT01992094",
      "title": "Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "QIVc",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIV1c",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIV2c",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2680,
      "start_date": "2013-11",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2015-12-10",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 40,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 33 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01992094"
    },
    {
      "nct_id": "NCT02914275",
      "title": "A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Seqirus Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Comparator Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "6 Months to 59 Months"
      },
      "enrollment_count": 2250,
      "start_date": "2016-09-27",
      "completion_date": "2017-08-11",
      "has_results": true,
      "last_update_posted_date": "2019-01-23",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02914275"
    },
    {
      "nct_id": "NCT02915302",
      "title": "Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone Quadrivalent vaccine, No Preservative",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "35 Months",
        "sex": "ALL",
        "summary": "6 Months to 35 Months"
      },
      "enrollment_count": 1950,
      "start_date": "2016-09-23",
      "completion_date": "2017-03-06",
      "has_results": true,
      "last_update_posted_date": "2022-03-29",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Harrisburg, Arkansas • Downey, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Harrisburg",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915302"
    },
    {
      "nct_id": "NCT02473510",
      "title": "Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 301,
      "start_date": "2015-06",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2016-11-28",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 3,
      "location_summary": "South Miami, Florida • Stockbridge, Georgia • Portland, Oregon",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02473510"
    },
    {
      "nct_id": "NCT04697576",
      "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage I Cutaneous Melanoma AJCC v8",
        "Clinical Stage IA Cutaneous Melanoma AJCC v8",
        "Clinical Stage IB Cutaneous Melanoma AJCC v8",
        "Clinical Stage II Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIA Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIB Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIC Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab + Relatlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Carlo Contreras",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2021-10-20",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04697576"
    },
    {
      "nct_id": "NCT04667117",
      "title": "A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Quadrivalent influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        },
        {
          "name": "iDMT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2021-01-14",
      "completion_date": "2023-07-06",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04667117"
    },
    {
      "nct_id": "NCT05624606",
      "title": "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Influenza mRNA Vaccine MRT5410",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Influenza vaccine RIV4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Inactivated Influenza Standard Dose QIV-SD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Inactivated Influenza High Dose QIV-HD",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 682,
      "start_date": "2022-11-28",
      "completion_date": "2024-03-28",
      "has_results": false,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-09-02T07:56:04.197Z",
      "location_count": 23,
      "location_summary": "Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more",
      "locations": [
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05624606"
    }
  ]
}